Edwards Lifesciences (EW) Change in Accured Expenses (2009 - 2026)

Edwards Lifesciences' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at -$347.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 235.69% year-over-year to -$347.1 million; the TTM figure through Mar 2026 stood at $151.4 million (up 101.33% YoY), while the FY2025 annual figure was $395.1 million, up 341.45% from the prior year.
• Change in Accured Expenses was -$347.1 million for Q1 2026 at Edwards Lifesciences, down from $168.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $226.1 million in Q3 2025 to a low of -$347.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $15.4 million across 5 years, with a median of $29.9 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses slumped 1074.19% in 2022, then surged 5541.94% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $34.3 million in 2022, then retreated by 2.62% to $33.4 million in 2023, then slumped by 109.28% to -$3.1 million in 2024, then soared by 5541.94% to $168.7 million in 2025, then sank by 305.75% to -$347.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$347.1 million (Q1 2026), $168.7 million (Q4 2025), and $226.1 million (Q3 2025), per Business Quant data.